Memantine HCL Articles
Insights on the US Alzheimer's disease market
3 December 2012
Forest Labs, Gedeon Richter plan 2012 filing for cariprazine
29 February 2012
Combination treatment with memantine and ChEI suggests a comprehensive effect on patients with Alzheimer’s
13 September 2011
Forest/Merz settle with Mylan and others of generic Namenda; Impax’ generic Opana cleared in USA
23 July 2010
Medivation slumps as Alzheimer’s drug candidate Dimebon, partnered with Pfizer, disappoints in Ph III
4 March 2010
Combo Alzheimer's drug that delays nursing home admission would earn higher patient share in the USA than Europe
18 February 2010
US mid-caps Biogen, Forest and Gilead post in-line or better-than-expected three-month results
21 October 2009
Forest Labs' profit up 8% on AD drug sales
10 November 2008
Namenda ER boosts cognitive performance
11 August 2008
Forest's EPS falls to $0.79 in 2nd-qtr 2008
4 August 2008
Forest Labs swings back to profit in fiscal 1st-qtr
21 April 2008
NT amends terms of memantine deal
3 March 2008
Forest's 28mg dose ER memantine impresses
14 February 2008
Stock Commentary - New York week to Jan 21, 2008
28 January 2008
Barr confirms Namenda patent challenge
21 January 2008
Lexapro and Namenda help Forest's income for fiscal 3rd-qtr soar 21%, beating estimates
21 January 2008
Forest's EPS drops 5% on Microbia charge
29 October 2007
Forest's income for fiscal 1st qtr soars 34%
23 July 2007
Forest records $238M loss for fiscal 4th-qtr
7 May 2007
Forest Labs 4th-qtr profit jumps 28%
29 January 2007
Stock Commentary - New York week to Oct 23, 2006
30 October 2006
Forest Lab's 1st-qtr net revenues leap 15%
24 July 2006
Japan stock market week to May 8, 2006
15 May 2006
Modest Merz makes millions from Alzheimer drug
15 August 2005
Aricept and Aciphex lead Eisai's growth
15 August 2005
Forest Labs' sales hit by Celexa competition
25 April 2005
Stock Commentary - New York
18 April 2005
Forest Labs cuts earnings forecast
11 April 2005
Correction
14 March 2005
UK NICE seeks to curb Alzheimer's drugs
7 March 2005
Aricept boosts Eisai's nine month results
28 February 2005
US volume Rx sales rise 8.3% in 2004
21 February 2005
Forest disappoints, despite 17% EPS hike
24 January 2005
Expanded use of Namenda on track
22 November 2004
Eisai 1st-half sales on target, rising 5.3%
15 November 2004
Forest beats 2nd-qtr targets; raises outlook
25 October 2004
Forest raises fiscal 2005 2nd-qtr earnings estimate
11 October 2004
1st-qtr turnover rises 5.2% at Eisai
9 August 2004
Neurobiological Tech buys Empire Pharma
26 July 2004
Merz' Axura shows benefits in AD
12 July 2004
Stock Commentary - New York
7 June 2004
Overseas sales boost Eisai's results
31 May 2004
Forest posts 20% jump in fiscal-2003 sales
3 May 2004
Merz
1 March 2004
Stock Commentary - New York
26 January 2004
Stock Commentary - New York
19 January 2004
Tokyo pharma stocks - week to Jan 12
19 January 2004
Forest to seek wider approval of Namenda for Alzheimer's disease
19 January 2004
Stock Commentary - New York
27 October 2003
Forest's earnings lifted by antidepressants
20 October 2003
Forest's Namenda on track for US approval
6 October 2003
Showing 1-67 of 67 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
